Also known as: advanced Parkinson's disease, advanced Parkinson’s disease
Parkinson's disease is a progressive neurodegenerative disorder affecting movement and non-motor functions, driven by degeneration of dopamine-producing neurons in the brain.
Alumis reported that 54% of psoriasis patients achieved complete skin clearance (PASI 100) at 48 weeks in the ONWARD3 study, with 75% achieving PASI 90. The company plans to submit an NDA for envudeucitinib in Q4 2026.
Alpha-synuclein biomarkers in saliva, skin, and CSF show diagnostic promise for Parkinson's disease, with seed amplification assays demonstrating high sensitivity and specificity. Salivary gland biopsies and oral brushings are being studied as less invasive detection methods, though clinical implementation still faces challenges.
FDA cleared Quantum Biopharma's IND for a Phase 2 trial of Lucid-MS in MS. Biogen's BIIB091 Phase 2 trial reached completion, and Bial concluded its ACTIVATE Phase IIb treatment period for GBA-PD.
Oncotelic granted Lunai Bioworks worldwide rights to its nose-to-brain delivery system for biodefense and Alzheimer's. Nearly 98% of small-molecule drugs fail to cross the blood-brain barrier.
AbbVie's Q2 2026 revenue hit $16.99 billion, beating estimates, but full-year EPS guidance was cut to $13.97. Growth in immunology and neuroscience continued, and the FAST study on ubrogepant wrapped up.
The global CNS therapeutics market was valued at USD 127.29 billion in 2025 and is projected to reach USD 285.72 billion by 2035, driven by demand for Alzheimer’s and Parkinson’s treatments. North America held 45% of the market; neurodegenerative diseases were the largest segment. Private investment and trends toward biologics and AI are shaping the sector.
Prothena Corporation plc will report its second quarter and first six months of 2026 financial results on August 6, 2026, after U.S. market close. No conference call will be held, consistent with past practice. The company focuses on neurodegenerative and rare amyloid diseases.
BIIB122 failed to slow Parkinson's progression in the Phase 2b LUMA study, missing primary and secondary endpoints. Biogen and Denali will discontinue the drug in idiopathic Parkinson's disease; Denali continues the BEACON study in LRRK2 carriers.
Serina Therapeutics completes sentinel dosing in Cohort 1 of its Phase Ib registrational trial of SER-252 for advanced Parkinson's disease. Safety review recommends continuation; enrollment and dosing ongoing. FDA alignment on 505(b)(2) pathway and registrational status.
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07777484 |
An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination in Individuals Who Have Previously Undergone aSyn Immunotherapy |
RECRUITING | PHASE1 |
| NCT07772622 |
The Validity and Reliability of an Improved Paper Grasping Test for Parkinson's Disease |
COMPLETED | |
| NCT07733349 |
Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07720869 |
Effects of Wild Blueberry Ingestion on Motor Performance of People With Parkinson's Disease |
COMPLETED | PHASE1 |
| NCT07703137 |
NAD Supplementation in Parkinson's Disease |
ENROLLING_BY_INVITATION | NA |
| NCT07698236 |
Temporal Interference Noninvasive Deep Brain Stimulation for Idiopathic Parkinson's Disease and Parkinsonian Syndromes: Effects and Target Exploration |
ENROLLING_BY_INVITATION | NA |
| NCT07678983 |
Whole-Body Vibration in Parkinson Disease |
ACTIVE_NOT_RECRUITING | NA |
| NCT07653256 |
HF-rTMS Primed Balance Training on Corticomotor Excitability, Balance, and Gait in Parkinson's |
NOT_YET_RECRUITING | NA |
| NCT07644013 |
Prospective Multicenter Registry Study of Multiple System Atrophy in China |
RECRUITING | |
| NCT07629115 |
A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product. |
RECRUITING |
